Open Access
Med Sci (Paris)
Volume 38, Number 1, Janvier 2022
Page(s) 32 - 37
Section M/S Revues
Published online 21 January 2022
  1. Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med 2017 ; 377 : 1119–1131. [CrossRef] [PubMed] [Google Scholar]
  2. Nidorf SM, Fiolet ATL, Mosterd A, et al. Colchicine in Patients with Chronic Coronary Disease. N Engl J Med 2020; 383 : 1838–47. [CrossRef] [PubMed] [Google Scholar]
  3. Ait-Oufella H, Libby P, Tedgui A. Anticytokine Immune Therapy and Atherothrombotic Cardiovascular Risk. Arterioscler Thromb Vasc Biol 2019 ; 39 : 1510–1519. [CrossRef] [PubMed] [Google Scholar]
  4. Bouchon A, Dietrich J, Colonna M. Cutting edge : inflammatory responses can be triggered by TREM-1, a novel receptor expressed on neutrophils and monocytes. J Immunol 2000 ; 164 : 4991–4995. [CrossRef] [PubMed] [Google Scholar]
  5. Bouchon A, Facchetti F, Weigand MA, Colonna M. TREM-1 amplifies inflammation and is a crucial mediator of septic shock. Nature 2001 ; 410 : 1103–1107. [CrossRef] [PubMed] [Google Scholar]
  6. Gorlier C, Sellam J, Laurans L, et al. In familial Mediterranean fever, soluble TREM-1 plasma level is higher in case of amyloidosis. Innate Immun 2019 ; 25 : 487–490. [CrossRef] [PubMed] [Google Scholar]
  7. Klesney-Tait J, Turnbull IR, Colonna M. The TREM receptor family and signal integration. Nat Immunol 2006 ; 7 : 1266–1273. [CrossRef] [PubMed] [Google Scholar]
  8. Gibot S, Kolopp-Sarda MN, Bene MC, et al. A soluble form of the triggering receptor expressed on myeloid cells-1 modulates the inflammatory response in murine sepsis. J Exp Med 2004 ; 200 : 1419–1426. [CrossRef] [PubMed] [Google Scholar]
  9. Dower K, Ellis DK, Saraf K, et al. Innate immune responses to TREM-1 activation : overlap, divergence, and positive and negative cross-talk with bacterial lipopolysaccharide. J Immunol 2008 ; 180 : 3520–3534. [CrossRef] [PubMed] [Google Scholar]
  10. Zanzinger K, Schellack C, Nausch N, Cerwenka A. Regulation of triggering receptor expressed on myeloid cells 1 expression on mouse inflammatory monocytes. Immunology 2009 ; 128 : 185–195. [CrossRef] [PubMed] [Google Scholar]
  11. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005 ; 352 : 1685–1695. [Google Scholar]
  12. Combadiere C, Potteaux S, Rodero M, et al. Combined inhibition of CCL2, CX3CR1 and CCR5 abrogates Ly6C(hi) and Ly6C(lo) monocytosis and almost abolishes atherosclerosis in hypercholesterolemic mice. Circulation 2008 ; 117 : 1649–1657. [CrossRef] [PubMed] [Google Scholar]
  13. Chinetti-Gbaguidi G, Colin S, Staels B. Macrophage subsets in atherosclerosis. Nat Rev Cardiol 2015 ; 12 : 10–17. [CrossRef] [PubMed] [Google Scholar]
  14. Joffre J, Potteaux S, Zeboudj L, et al. Genetic and Pharmacological Inhibition of TREM-1 Limits the Development of Experimental Atherosclerosis. J Am Coll Cardiol 2016 ; 68 : 2776–2793. [CrossRef] [PubMed] [Google Scholar]
  15. Zysset D, Weber B, Rihs S, et al. TREM-1 links dyslipidemia to inflammation and lipid deposition in atherosclerosis. Nat Commun 2016 ; 7 : 13151. [CrossRef] [PubMed] [Google Scholar]
  16. Frangogiannis NG. The inflammatory response in myocardial injury, repair, and remodelling. Nat Rev Cardiol 2014 ; 11 : 255–265. [Google Scholar]
  17. Vinten-Johansen J.. Involvement of neutrophils in the pathogenesis of lethal myocardial reperfusion injury. Cardiovasc Res 2004 ; 61 : 481–497. [CrossRef] [PubMed] [Google Scholar]
  18. Carrasco K, Boufenzer A, Jolly L, et al. TREM-1 multimerization is essential for its activation on monocytes and neutrophils. Cell Mol Immunol 2019 ; 16 : 460–472. [CrossRef] [PubMed] [Google Scholar]
  19. Boufenzer A, Carrasco K, Jolly L, et al. Potentiation of NETs release is novel characteristic of TREM-1 activation and the pharmacological inhibition of TREM-1 could prevent from the deleterious consequences of NETs release in sepsis. Cell Mol Immunol 2021; 18 : 452–60. [CrossRef] [PubMed] [Google Scholar]
  20. Boufenzer A, Lemarie J, Simon T, et al. TREM-1 Mediates Inflammatory Injury and Cardiac Remodeling Following Myocardial Infarction. Circ Res 2015 ; 116 : 1772–1782. [CrossRef] [PubMed] [Google Scholar]
  21. Lemarie J, Boufenzer A, Popovic B, et al. Pharmacological inhibition of the triggering receptor expressed on myeloid cells-1 limits reperfusion injury in a porcine model of myocardial infarction. ESC Heart Fail 2015 ; 2 : 90–99. [CrossRef] [PubMed] [Google Scholar]
  22. Szigeti K, Horvath I, Veres DS, et al. A novel SPECT-based approach reveals early mechanisms of central and peripheral inflammation after cerebral ischemia. J Cereb Blood Flow Metab 2015 ; 35 : 1921–1929. [CrossRef] [PubMed] [Google Scholar]
  23. Stanley D, Mason LJ, Mackin KE, et al. Translocation and dissemination of commensal bacteria in post-stroke infection. Nat Med 2016 ; 22 : 1277–1284. [CrossRef] [PubMed] [Google Scholar]
  24. Liu Q, Johnson EM, Lam RK, et al. Peripheral TREM1 responses to brain and intestinal immunogens amplify stroke severity. Nat Immunol 2019 ; 20 : 1023–1034. [CrossRef] [PubMed] [Google Scholar]
  25. Golledge J, Muller J, Daugherty A, Norman P. Abdominal aortic aneurysm : pathogenesis and implications for management. Arterioscler Thromb Vasc Biol 2006 ; 26 : 2605–2613. [CrossRef] [PubMed] [Google Scholar]
  26. Nordon IM, Hinchliffe RJ, Loftus IM, Thompson MM. Pathophysiology and epidemiology of abdominal aortic aneurysms. Nat Rev Cardiol 2011 ; 8 : 92–102. [CrossRef] [PubMed] [Google Scholar]
  27. Yuan Z, Lu Y, Wei J, et al. Abdominal Aortic Aneurysm : Roles of Inflammatory Cells. Front Immunol 2020; 11 : 609161. [Google Scholar]
  28. Vandestienne M, Zhang Y, Santos-Zas I, et al. TREM-1 orchestrates angiotensin II-induced monocyte trafficking and promotes experimental abdominal aortic aneurysm. J Clin Invest 2021; 131. [Google Scholar]
  29. Rao VH, Rai V, Stoupa S, et al. Tumor necrosis factor-alpha regulates triggering receptor expressed on myeloid cells-1-dependent matrix metalloproteinases in the carotid plaques of symptomatic patients with carotid stenosis. Atherosclerosis 2016 ; 248 : 160–169. [CrossRef] [PubMed] [Google Scholar]
  30. Vazquez CMP, Costa JO, Bomfim LGS, et al. Oxidized Low-Density Lipoprotein (Ox-LDL) and Triggering Receptor-Expressed Myeloid Cell (TREM-1) Levels Are Associated with Cardiometabolic Risk in Nonobese, Clinically Healthy, and Young Adults. Oxid Med Cell Longev 2019 ; 2019 : 7306867. [PubMed] [Google Scholar]
  31. Weber B, Schuster S, Zysset D, et al. TREM-1 deficiency can attenuate disease severity without affecting pathogen clearance. PLoS Pathog 2014 ; 10 : e1003900. [CrossRef] [PubMed] [Google Scholar]
  32. Cuvier V, Lorch U, Witte S, et al. A first-in-man safety and pharmacokinetics study of nangibotide, a new modulator of innate immune response through TREM-1 receptor inhibition. Br J Clin Pharmacol 2018 ; 84 : 2270–2279. [CrossRef] [PubMed] [Google Scholar]
  33. Francois B, Wittebole X, Ferrer R, et al. Nangibotide in patients with septic shock : a Phase 2a randomized controlled clinical trial. Intensive Care Med 2020; 46 : 1425–37. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.